IN2012DN00412A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00412A IN2012DN00412A IN412DEN2012A IN2012DN00412A IN 2012DN00412 A IN2012DN00412 A IN 2012DN00412A IN 412DEN2012 A IN412DEN2012 A IN 412DEN2012A IN 2012DN00412 A IN2012DN00412 A IN 2012DN00412A
- Authority
- IN
- India
- Prior art keywords
- fibrosis
- tgfbetarii
- lopm
- skin
- suitably
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22933409P | 2009-07-29 | 2009-07-29 | |
PCT/EP2010/060867 WO2011012609A2 (en) | 2009-07-29 | 2010-07-27 | Ligands that bind tgf-beta receptor rii |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN00412A true IN2012DN00412A (ru) | 2015-05-22 |
Family
ID=43067099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN412DEN2012 IN2012DN00412A (ru) | 2009-07-29 | 2010-07-27 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9109031B2 (ru) |
EP (1) | EP2459593A2 (ru) |
JP (2) | JP2013500030A (ru) |
KR (1) | KR20120063475A (ru) |
CN (1) | CN102574922A (ru) |
AU (1) | AU2010277629B2 (ru) |
BR (1) | BR112012001977A2 (ru) |
CA (1) | CA2768981A1 (ru) |
EA (1) | EA026097B1 (ru) |
IL (1) | IL217458A0 (ru) |
IN (1) | IN2012DN00412A (ru) |
MX (1) | MX2012001278A (ru) |
SG (1) | SG178135A1 (ru) |
WO (1) | WO2011012609A2 (ru) |
ZA (1) | ZA201200372B (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012093125A1 (en) * | 2011-01-06 | 2012-07-12 | Glaxo Group Limited | Ligands that bind tgf-beta receptor ii |
US20190119387A1 (en) | 2016-04-05 | 2019-04-25 | Glaxosmithkline Intellectual Property Development Limited | Inhibition of tgfbeta in immunotherapy |
GB201608052D0 (en) * | 2016-05-09 | 2016-06-22 | Univ Oslo Hf | T-cell receptors which recognise frameshift mutants of TGF-beta RII |
WO2018057522A1 (en) * | 2016-09-20 | 2018-03-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Harnessing protein-based drugs comprising an anchor domain for use on the ocular surface |
JP2020526218A (ja) | 2017-07-14 | 2020-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 移植拒絶リスクを予測する新規の方法 |
WO2019173829A1 (en) | 2018-03-09 | 2019-09-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Delivering biological drugs to tissues |
GB201807693D0 (en) * | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
IL305181A (en) | 2021-02-15 | 2023-10-01 | Takeda Pharmaceuticals Co | Cell therapy compositions and methods for modulating TGF-B signaling |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
JP2001206899A (ja) | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | TGF−βII型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
EP1399484B1 (en) | 2001-06-28 | 2010-08-11 | Domantis Limited | Dual-specific ligand and its use |
US20030028905A1 (en) * | 2001-07-31 | 2003-02-06 | Petra Knaus | Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms |
AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
ATE328906T1 (de) | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
JP2004121001A (ja) * | 2002-08-07 | 2004-04-22 | Japan Tobacco Inc | TGF−βII型受容体に対する高親和性モノクローナル抗体 |
WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
WO2004101790A1 (en) | 2003-05-14 | 2004-11-25 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
CA2529819A1 (en) | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
PT1737962E (pt) | 2004-03-24 | 2010-12-03 | Domantis Ltd | Sequência líder universal gas1 |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
CA2636854A1 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind il-4 and/or il-13 |
GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
-
2010
- 2010-07-27 KR KR1020127005555A patent/KR20120063475A/ko not_active Application Discontinuation
- 2010-07-27 JP JP2012522147A patent/JP2013500030A/ja active Pending
- 2010-07-27 IN IN412DEN2012 patent/IN2012DN00412A/en unknown
- 2010-07-27 CA CA2768981A patent/CA2768981A1/en not_active Abandoned
- 2010-07-27 SG SG2012006029A patent/SG178135A1/en unknown
- 2010-07-27 EA EA201290028A patent/EA026097B1/ru not_active IP Right Cessation
- 2010-07-27 CN CN2010800450323A patent/CN102574922A/zh active Pending
- 2010-07-27 BR BR112012001977A patent/BR112012001977A2/pt not_active Application Discontinuation
- 2010-07-27 AU AU2010277629A patent/AU2010277629B2/en not_active Ceased
- 2010-07-27 WO PCT/EP2010/060867 patent/WO2011012609A2/en active Application Filing
- 2010-07-27 EP EP10735014A patent/EP2459593A2/en not_active Withdrawn
- 2010-07-27 MX MX2012001278A patent/MX2012001278A/es not_active Application Discontinuation
- 2010-07-27 US US13/387,376 patent/US9109031B2/en not_active Expired - Fee Related
-
2012
- 2012-01-10 IL IL217458A patent/IL217458A0/en unknown
- 2012-01-17 ZA ZA2012/00372A patent/ZA201200372B/en unknown
-
2015
- 2015-10-09 JP JP2015201067A patent/JP2016053039A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2011012609A2 (en) | 2011-02-03 |
SG178135A1 (en) | 2012-03-29 |
ZA201200372B (en) | 2013-06-26 |
IL217458A0 (en) | 2012-02-29 |
CA2768981A1 (en) | 2011-02-03 |
JP2016053039A (ja) | 2016-04-14 |
CN102574922A (zh) | 2012-07-11 |
EA201290028A1 (ru) | 2012-08-30 |
JP2013500030A (ja) | 2013-01-07 |
BR112012001977A2 (pt) | 2017-01-31 |
AU2010277629B2 (en) | 2016-05-19 |
AU2010277629A1 (en) | 2012-02-16 |
US20120129778A1 (en) | 2012-05-24 |
EA026097B1 (ru) | 2017-03-31 |
WO2011012609A3 (en) | 2011-09-15 |
MX2012001278A (es) | 2012-03-16 |
EP2459593A2 (en) | 2012-06-06 |
KR20120063475A (ko) | 2012-06-15 |
US9109031B2 (en) | 2015-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN00412A (ru) | ||
JP7007333B2 (ja) | 抗炎症活性を有するペプチド、及びそれを含む組成物 | |
JP6788062B2 (ja) | 抗炎症活性を有するペプチド、及びそれを含む組成物 | |
MX2013007936A (es) | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta. | |
WO2013184960A3 (en) | Chimeric fibroblast growth factor 23 proteins and methods of use | |
AU2015202477B2 (en) | Antibodies that bind csf1r | |
HRP20151227T1 (hr) | Sastavi i postupci uporabe za terapeutska protutijela | |
EA201201047A1 (ru) | Способы и композиции, в которых применяют слитые полипептиды fgf 23 | |
Hovanessian | Midkine, a cytokine that inhibits HIV infection by binding to the cell surface expressed nucleolin | |
JP6797810B2 (ja) | Cd40l関連疾患または障害を治療するための抗cd40l抗体及び方法 | |
HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
SI3134430T1 (en) | ENVIRONMENTAL PROTEINS TRAIL RECEPTORS AGENTS | |
WO2019147944A8 (en) | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents | |
EP3345925A3 (en) | Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods | |
JP2013514992A5 (ru) | ||
KR20120137270A (ko) | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 | |
RU2678810C2 (ru) | ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα | |
JP2024001292A (ja) | 多特異性Wnt代替分子及びその使用 | |
MX2022005850A (es) | Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo. | |
RU2011110459A (ru) | Рекомбинантно полученный человеческий фактор viii и ix | |
Song et al. | Arginines in the CDR of anti‐dsDNA autoantibodies facilitate cell internalization via electrostatic interactions | |
NZ599114A (en) | Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists | |
WO2015138784A3 (en) | Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis | |
WO2008060814A3 (en) | ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF | |
CA2739083C (en) | Translocation interfering toll-like receptor 3(tlr3) variants for suppressing toll-like receptor activity and uses thereof |